Form 8-K BridgeBio Pharma, Inc. For: Jan 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
BridgeBio issues $632.5 million convertible notes due 2033
January 21, 2026 4:14 PM ESTBridgeBio Pharma Inc. (NASDAQ: BBIO) issued $632.5 million in convertible senior notes due 2033 through a private offering to qualified institutional buyers on January 21, 2026, according to a company statement.
The notes carry a 0.75% annual interest rate and mature on February 1, 2033. Interest payments occur semiannually on February 1 and August 1, beginning August 1, 2026.... More
